We sought to determine the degree of correlation between the condition of the patellar articular cartilage and patellofemoral symptoms and function in osteoarthritic patients undergoing total knee arthroplasty. The depth of the osteoarthritic lesion, as graded by the Outerbridge classification and its size and location were assessed to determine the condition of the patellar cartilage in 80 consecutive osteoarthritic knees undergoing total knee arthroplasty. The association between the condition of the cartilage and patellofemoral symptoms and function was investigated by correlation analysis. The depth and size of the lesion had a significant but weak correlation with anterior knee pain (r = -0.300 and -0.289; p = 0.007 and 0.009, respectively), whereas location had no significant association (p > 0.05). None had a significant association with patellofemoral functional parameters (chair-rising, stair-climbing, and quadriceps power) (p > 0.05). Our study indicates that patellofemoral symptoms and function are not completely determined by the condition of the cartilage. Caution should be taken when the symptoms and functional limitations are attributed to a lesion in the patellofemoral joint in making a decision regarding patellar resurfacing in total knee arthroplasty.

No abstract

No abstract

No abstract

BackgroundPrevious study using cluster analysis technique analyzed the association between comorbidities and various outcome measures in patients with axial spondyloarthritis (axSpA). Due to the cross-sectional nature of the study, however, prognostic information about each group were not provided.ObjectivesThis study aims to perform cluster analysis to differentiate axSpA patients in terms of comorbidities and to examine the differential treatment outcomes of these groups using the data retrieved from Korean College of Rheumatology Biologics (KOBIO) registry which includes longitudinal data of axSpA patients using anti-TNF agents.MethodsClinical characteristics and demographic data of axSpA patients in KOBIO registry were analyzed using an agglomerative hierarchical cluster analysis. The optimum number of clusters was determined by the pseudo-F statistic. After clustering, baseline clinical characteristics and treatment outcomes were compared between isolated axSpA and classified comorbidity groups using multivariable linear models and mixed linear models, respectively.Results1,207 patients were included in the study. At least one comorbidity was seen in 464 (38%) axSpA patients. Compared with those with isolated axSpA, patients with comorbidity were older, longer disease duration, and reported higher PtGA (p = 0.019), and BASFI (p <0.001), but did not have significantly different BASDAI, ESR, and CRP levels. The most common comorbidities were hypertension (14.4%), hyperlipidemia (13.0%), and obesity (4.5%). The hierarchical cluster analysis classified patients in 21 groups. We combined clusters 17-21 for further evaluation due to the small size of clusters (<5 patients). In multivariable linear models for baseline clinical characteristics, we found that patients in the hypothyroidism, asthma, and headache clusters reported poorer PtGA, BASDAI, or BASFI, and the weight loss cluster had higher level of CRP, compared with patients with isolated axSpA even after adjustment of patient demographic data. After 1-year treatment of anti-TNF agents, the patients in the hypothyroidism and weight loss clusters decreased greater amounts of BASDAI and BASFI scores and ESR/CRP levels, respectively, compared with patients with isolated axSpA (Table 1). However, the degree of improvement in asthma and headache clusters, which had higher disease activities at baseline, was similar with isolated axSpA. Therefore, they still had higher disease activity scores at the 1-year follow-up.Table 1.Comparing each cluster to patients with isolated axSpA (i.e. no comorbidity) using multivariable linear mixed models for each treatment outcome measure at 1-year follow-up as the dependent variable.Cluster/descriptionPtGABASDAIBASFIESRCRP2isolated axSpA-----3Obesity0.233 (-0.57 - 1.036)0.098 (-0.648 - 0.844)-0.078 (-0.811 - 0.656)9.005 (0.481 - 17.529)†0.358 (-0.553 - 1.269)10Hypothyroidism-1.243 (-3.139 - 0.653)-2.147 (-3.908 - -0.385)†-2.38 (-4.076 - -0.684)†2.234 (-18.11 - 22.578)-0.087 (-2.123 - 1.95)11Weight loss-0.618 (-2.804 - 1.568)-0.901 (-2.932 - 1.131)-1.93 (-3.886 - 0.026)-26.891 (-50.351 - -3.431)†-4.197 (-6.544 - -1.849)†15Asthma0.049 (-2.138 - 2.235)0.833 (-1.199 - 2.864)0.254 (-1.702 - 2.209)-1.058 (-24.517 - 22.402)2.018 (-0.552 - 4.589)16Headache-0.103 (-1.052 - 0.846)0.169 (-0.713 - 1.051)0.463 (-0.387 - 1.312)0.344 (-9.693 - 10.382)-0.046 (-1.132 - 1.04)† p-value < 0.05. Only clusters including significant results were shown due to the limitation oft he number of characters.ConclusionComorbidity could affect the treatment outcomes in patients with axSpA in certain subgroups. Thus, we should also pay attention to the comorbidities when treating axSpA.Disclosure of InterestsNone declared